Top Markets
#1 ONFA ONFA +217.91%
#2 Resolv wstUSR Resolv wstUSR +198.08%
#3 Noon Noon +41.33%
#4 Doge Strategy Doge Strategy +38.28%
#5 DeAgentAI DeAgentAI +36.64%
#6 NKN NKN +34.87%
#7 StakeStone StakeStone +29.44%
#8 BLOCKv BLOCKv +25.50%
#9 KONET KONET +24.76%
#10 OpenVPP OpenVPP +21.34%
Coin of the day
ONFA ONFA
Configuración
Idioma
ESPAñOL
Moneda
USD
Tema
Ensysce Biosciences, Inc. Ensysce Biosciences, Inc.

Ensysce Biosciences, Inc.

ENSC
Clasificación en acciones #19706
Ensysce Biosciences, Inc., a clinical-stage pharmaceutical company, engages in... Ensysce Biosciences, Inc., a clinical-stage pharmaceutical company, engages in developing various prescription drugs for severe pain relief in opioid addiction, misuse, abuse, and overdose in the United States. It develops products using Trypsin Activated Abuse Protection platform, an abuse-resistant opioid prodrug technology; and Multi-Pill Abuse Resistance platform, an over-dose protection opioid prodrug technology. The company is developing PF614, a TAAP prodrug candidate of oxycodone, which is in Phase II clinical trial for the treatment of acute or chronic pain; and PF614-MPAR, a combination product of PF614 and nafamostat that is in Phase I clinical trial for overdose protection against excessive oral ingestion, as well as an oral and inhalation drug product of nafamostat for use against coronaviral infections and other pulmonary diseases, such as cystic fibrosis. It is also developing PF329, an extended-release prodrug of hydromorphone that is similar to PF614; PF8001 and PF8026 are extended and immediate-release prodrugs of amphetamine for ADHD medication abuse; and PF26810, an extended-release prodrug of methadone for opioid use disorder. The company is based in La Jolla, California.
Precio por acción
$0.5275
Capitalización bursátil
$1.25M
Cambio (1 día)
-3.56%
Cambio (1 año)
-83.77%
País
US
Comercio Ensysce Biosciences, Inc. (ENSC)

Categoría

Healthcare
Ratio P/S de Ensysce Biosciences, Inc. (ENSC)
Ratio P/S al March 2026 TTM: 0.22
Según los informes financieros más recientes y el precio de las acciones de Ensysce Biosciences, Inc., el ratio P/S actual (TTM) es 0.22. Al final de 2023, el ratio P/S era 16.14.
Historial del ratio P/S de Ensysce Biosciences, Inc. desde 2017 hasta 2026
Ratio P/S al final de cada año
Año Ratio P/S Cambiar
2026 (TTM) 0.22 -92.12%
2024 2.73 -83.08%
2023 16.14 67.59%
2022 9.63 -97.61%
2021 402.60 -99.21%
2020 50.77K -60.81%
2019 129.53K 0.00%
2018 0.00 0.00%
2017 0.00 0.00%
Ratio P/S de empresas similares o competidoras
Empresa Ratio P/S Diferencia del ratio P/S País
Novo Nordisk A/S Novo Nordisk A/S
Novo Nordisk A/S
NVO.US
3.55 1,551.86%
DK
Vertex Pharmaceuticals Incorporated Vertex Pharmaceuticals Incorporated
Vertex Pharmaceuticals Incorporated
VRTX.US
9.90 4,505.91%
US
Regeneron Pharmaceuticals, Inc. Regeneron Pharmaceuticals, Inc.
Regeneron Pharmaceuticals, Inc.
REGN.US
5.40 2,412.79%
US
UCB SA UCB SA
UCB SA
UCB.BR
6.14 2,754.88%
BE
CSL Limited CSL Limited
CSL Limited
CSL.AX
3.04 1,315.72%
AU